Quest Diagnostics (DGX) officer nets stock from award while covering taxes

Rhea-AI Filing Summary

Quest Diagnostics executive Michael J. Deppe reported offsetting equity transactions involving company stock. He acquired 1,473 shares of Quest Diagnostics common stock on a grant/award basis tied to a performance stock award, valued at $204.86 per share, increasing his holdings at that moment to 35,946 shares.

On the same date, 750 shares were disposed of back to Quest Diagnostics at $204.86 per share solely to cover tax withholding obligations arising from the settlement of that performance stock award. After the tax-withholding disposition, Deppe directly owned 35,196 shares of Quest Diagnostics common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Deppe Michael J

Role SVP, Corp. Controller & CAO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,473	$204.86	$302K
Tax Withholding	Common Stock	750	$204.86	$154K

Holdings After Transaction: Common Stock — 35,946 shares (Direct)

Footnotes (1)

1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d). Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Deppe Michael J

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Corp. Controller & CAO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		1,473(1)	A	$204.86	35,946	D
Common Stock	03/04/2026		F		750(2)	D	$204.86	35,196	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance stock award.

Remarks:

	Sean D. Mersten, Attorney in Fact for Michael J. Deppe	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Quest Diagnostics (DGX) executive Michael J. Deppe report?

Michael J. Deppe reported one acquisition and one disposition of Quest Diagnostics common stock. He received 1,473 shares through a performance stock award and disposed of 750 shares back to the company to satisfy tax withholding obligations from that award.

How many Quest Diagnostics (DGX) shares did Michael J. Deppe receive in the award?

Michael J. Deppe received 1,473 shares of Quest Diagnostics common stock. These shares were issued in settlement of a performance stock award that had been approved under Rule 16b-3(d), representing equity-based compensation rather than an open-market stock purchase.

Why did Michael J. Deppe dispose of Quest Diagnostics (DGX) shares in this Form 4?

He disposed of 750 Quest Diagnostics shares back to the issuer. The footnotes state this disposition was solely to cover tax withholding obligations arising from the settlement of the performance stock award, meaning it functioned as a tax-withholding transaction, not an open-market sale.

What price per share was reported for Michael J. Deppe’s Quest Diagnostics (DGX) transactions?

Both the acquisition and disposition transactions used a reported price of $204.86 per Quest Diagnostics share. This price was applied to the 1,473-share performance stock award settlement and to the 750-share tax-withholding disposition back to the company.

How many Quest Diagnostics (DGX) shares does Michael J. Deppe own after these transactions?

Following these transactions, Michael J. Deppe directly owns 35,196 shares of Quest Diagnostics common stock. This figure reflects the net impact of receiving 1,473 shares from the performance award and disposing of 750 shares to cover associated tax withholding.

Were Michael J. Deppe’s Quest Diagnostics (DGX) transactions open-market buys or sells?

No, the transactions were not open-market trades. The Form 4 classifies the acquisition as a grant or award of 1,473 shares and the disposition of 750 shares as a tax-withholding transaction, where shares were delivered back to the issuer to satisfy tax liabilities.